Neurocrine Biosciences Stock Price and Value Analysis

Neurocrine Biosciences (NasdaqGS:NBIX) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Neurocrine Biosciences to reach your target.

Target type

NBIX Free Cash Flow Trend

Free Cash Flow trendline for NBIX
Free Cash Flow trendline for Neurocrine Biosciences
CSV

Based on historical returns, we believe that Neurocrine Biosciences can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the NBIX Numbers

NBIX Price
(Neurocrine Biosciences stock price per share)
$156.59
[?] NBIX Fair Price
(based on intrinsic value)
$26.48
[?] NBIX Safety Price (based on a variable margin of safety) $17.21
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 14% higher than other Healthcare stocks
[?] PE Ratio versus Industry 59% lower than other Biotechnology stocks
[?] Cash Yield -0.23%
[?] Free Cash Flow Jitter 97%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,900,825 shares shorted. With 99,907,862 shares available for purchase and an average trading volume over the past 10 trading days of 1,357,420, it would take at least 4.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 914475 -53.1
2010 914475 49.8
2011 914475 -1.1
2012 914475 -35.8
2013 914475 -30.1
2014 914475 -48
2015 914475 -39.2
2016 914475 -108
2017 914475 -97.4
2018 914475 93.5
2019 914475 137
2020 914475 216
2021 914475 240
2022 914475 321
2023 914475 371
2024 914475 572
2025 914475 755

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 10 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $2,805 million against net income of $1,822 million, or 1.54 times. Net income was negative in 7 of the 17 years, and those years are left out of the ratio.

In 2025, capital expenditures were $34 million, 4.3% of operating cash flow of $783 million, which leaves an estimated $749 million after capex. Across the 9 years with reported capex, it averaged 6.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -51 -53.1 0 n/a
2010 -8 49.9 0.3 n/a
2011 37.6 -0.7 0.8 -0.02
2012 5 -35.3 1 -7.02
2013 -46.1 -29.6 0.5 n/a
2014 -60.5 -47.1 1.6 n/a
2015 -88.9 -38 1.9 n/a
2016 -141 -106 4.1 n/a
2017 -143 -94.3 6.9 n/a
2018 21.1 101 24.8 4.81
2019 37 147 14.7 3.97
2020 407 229 10.9 0.56
2021 89.6 257 23.4 2.86
2022 155 339 16.5 2.20
2023 250 390 28.3 1.56
2024 341 595 38.2 1.74
2025 479 783 34 1.64

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3 million in 2009 and $2,861 million in 2025, a compound annual growth rate of 53.7% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 21.4% from 2024 to 2025.

Our estimated free cash flow was $755 million in 2025, 26.4% of revenue. In 2009 the estimated margin was negative 1799.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 3 -53.1 -1799.2%
2010 33.5 49.8 148.6%
2011 77.4 -1.1 -1.4%
2012 53.1 -35.8 -67.4%
2013 2.9 -30.1 -1032.2%
2015 19.8 -39.2 -198.1%
2016 15 -108 -720.1%
2017 162 -97.4 -60.2%
2018 451 93.5 20.7%
2019 788 137 17.3%
2020 1,046 216 20.7%
2021 1,134 240 21.2%
2022 1,489 321 21.6%
2023 1,887 371 19.7%
2024 2,355 572 24.3%
2025 2,861 755 26.4%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $713 million against total liabilities of $1,378 million, or 51.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 29.8% of total assets in 2025, compared with 86.6% in 2010, a decrease of 56.8 percentage points.

Stockholders equity was $3,253 million in 2025, compared with $19.3 million in 2010, a rise of 16716.2%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 23.8% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 144 54.1 125 19.3
2011 138 50.1 78.3 60.1
2012 196 63.8 41.6 154
2013 155 44.8 34.3 120
2014 243 31 34.3 209
2015 475 74.2 50.3 424
2016 365 83.3 50.2 315
2017 818 255 445 372
2018 993 142 512 481
2019 1,306 112 669 637
2020 1,735 187 609 1,126
2021 2,073 341 699 1,374
2022 2,369 263 661 1,708
2023 3,251 251 1,019 2,232
2024 3,719 233 1,129 2,590
2025 4,632 713 1,378 3,253

Price Versus Our Estimated Value

Only 9 of the 17 fiscal years under Neurocrine Biosciences's current filer show positive free cash flow.

Free cash flow is volatile from year to year, with a variability measure of 97%.

At $156.59, the price is above our fair value estimate of $26.48 for Neurocrine Biosciences.

We do not have a dividend yield for Neurocrine Biosciences.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 14% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 59% below the average for stocks in the Biotechnology industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Biotechnology industry, the ones closest in market capitalization to Neurocrine Biosciences, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Neurocrine Biosciences (NBIX) 15,850 23.2 - - 491% above
Bio-Techne Corporation (TECH) 11,420 66.7 0.3% 1.4% 91% above
Repligen Corporation (RGEN) 10,886 - - - 417% above
Biogen (BIIB) 36,531 107.0 - 10.1% 69% below
Amgen (AMGN) 237,363 25.4 2.2% 4.4% 11% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 914475.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 8 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: NBIX annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in NBIX

Does Neurocrine Biosciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: NBIX

This example shows how we apply the Trendshare checklist to NBIX: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 156.59
    • Market cap: $16B
    • EPS: 6.74
  2. Step 2 — Valuation checks

    • P/E: 23.233
    • FCF yield: -0.2%
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.